Can a common anesthetic be tailored for burn victims?
NCT ID NCT02048683
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial investigates how the body handles sevoflurane, an inhaled anesthetic used for short-term sedation, in burn patients in the intensive care unit (ICU). It compares drug levels in burn patients with those in other ICU patients to see if dosing needs adjustment. The study involves 24 adults on ventilators who require sedation, including those with burns covering 20-50% of their body. By measuring sevoflurane and its byproducts in the blood, researchers aim to refine sedation practices for this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sevoflurane (an inhaled anesthetic used for short-term sedation in the ICU)
- What this could lead to
- If successful, this could lead to more precise dosing of sevoflurane for sedation in burn patients, improving safety and effectiveness.
- What could go wrong
- This is a small early-phase study focused on drug levels, not clinical outcomes. Results may not apply broadly, and sevoflurane can have side effects like low blood pressure or breathing issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ICU PATIENTS WITH INDICATION OF SEDATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France